clinicaloncologyКлинический случай в онкологииClinical Case in Oncology3034-14773034-4018ОНКОПРАКТИК10.62546/3034-1477-2024-2-4-45-51clinicaloncology-91Research ArticleКЛИНИЧЕСКИЕ СЛУЧАИCASE REPORTSСлучай назначения ингибиторов CDK4/6 при метастатическом Her2-позитивном раке молочной железы в условиях СПб ГБУЗ «Городской клинический онкологический диспансер»Experience with prescribing CDK4/6 inhibitors for metastatic Her2-positive breast cancer in the St. Petersburg City Clinical Oncology Dispensaryhttps://orcid.org/0009-0001-9760-5641ЧистяковаЕ. А.ChistyakovaE. A.

Чистякова Елена Александровна Россия, 198255, Санкт-Петербург, 2-я Берёзовая аллея, д. 3/5

Chistyakova Elena Aleksandrovna2-ya Berezovaya Alley, 3/5, St. Petersburg, 193318, Russia

kegcumvino@yandex.ruhttps://orcid.org/0000-0002-8965-8364ГлузманМ. И.GluzmanM. I.

Марк И. Глузман Россия, 198255, Санкт-Петербург, 2-я Берёзовая аллея, д. 3/5

Mark I. Gluzman2-ya Berezovaya Alley, 3/5, St. Petersburg, 193318, Russia

АлборовА. Э.AlborovA. E.

Александр Э. Алборов Россия, 198255, Санкт-Петербург, 2-я Берёзовая аллея, д. 3/5

Aleksandr E. Alborov2-ya Berezovaya Alley, 3/5, St. Petersburg, 193318, Russia

ОганесянВ. А.OganesyanV. A.

Владимир А. Оганесян Россия, 198255, Санкт-Петербург, 2-я Берёзовая аллея, д. 3/5

Vladimir A. Oganesyan2-ya Berezovaya Alley, 3/5, St. Petersburg, 193318, Russia

https://orcid.org/0000-0003-4447-9458ОрловаР. В.OrlovaR. V.

Рашида В. Орлова Россия, 198255, Санкт-Петербург, 2-я Берёзовая аллея, д. 3/5

Rashida V. Orlova2-ya Berezovaya Alley, 3/5, St. Petersburg, 193318, Russia

СПб ГБУЗ «Городской клинический онкологический диспансер»РоссияSt. Petersburg City Clinical Oncology DispensaryRussian FederationСПб ГБУЗ «Городской клинический онкологический диспансер»; ФГБОУ ВО «Санкт-Петербургский государственный университет»РоссияSt. Petersburg City Clinical Oncology Dispensary; St. Petersburg State UniversityRussian Federation202428042025244551Copyright © Чистякова Е.А., Глузман М.И., Алборов А.Э., Оганесян В.А., Орлова Р.В., 20252025Чистякова Е.А., Глузман М.И., Алборов А.Э., Оганесян В.А., Орлова Р.В.Chistyakova E.A., Gluzman M.I., Alborov A.E., Oganesyan V.A., Orlova R.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.oncocase.ru/jour/article/view/91

Исследования препаратов из группы ингибиторов циклин-зависимых киназ 4/6 (CDK4/6) в качестве терапии первой линии на сегодняшний день не ограничиваются группой больных метастатическим люминальным Her2-негативным (ER+/HER2-) раком молочной железы (РМЖ). Ряд доклинических и клинических исследований продемонстрировал потенциал CDK4/6-ингибиторов в  лечении HER2-позитивного РМЖ с  положительной экспрессией гормональных рецепторов («трижды-    позитивный» подтип). Однако в этих исследованиях ингибиторы CDK4/6 применялись вместе с моноклональными антителами (трастузумаб, пертузумаб). В данной статье представлен случай применения комбинации ингибитора ароматазы и CDK4/6-ингибитора без использования химиотерапии и препаратов из группы моноклональных антител (МКА) в качестве первой линии лечения метастатического Her2-позитивного РМЖ в  условиях СПб ГБУЗ «Городской клинический онкологический диспансер». 

Studies of drugs from the group of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors as first-line therapy are currently not limited to the group of patients with metastatic luminal Her2-negative (ER+/HER2-) breast cancer. A number of preclinical and clinical studies have demonstrated the potential of CDK4/6 inhibitors in the treatment of HER2-positive breast cancer with positive expression of hormone receptors («triple-positive» subtype). However, in these studies, CDK4/6 inhibitors were used together with monoclonal antibodies (Trastuzumab, Pertuzumab). This article presents a case of using a combination of an aromatase inhibitor and a CDK4/6 inhibitor without chemotherapy and monoclonal antibody (MAB) drugs as a first-line treatment for metastatic Her2-positive breast cancer in the St. Petersburg City Clinical Oncology Dispensary.

Her2-позитивныйметастатический рак молочной железымоноклональные антителаингибиторы СDK4/6ингибиторы ароматазыHer2-positivemetastatic breast cancermonoclonal antibodiesCDK4/6 inhibitorsaromatase inhibitorsReferencesCameron D., Pickart-Gebhart M.J., Gelber R.D. et al. Eleven-year follow-up of patients treated with trastuzumab after adjuvant chemotherapy for HER2-positive early breast cancer: a final analysis of the HERceptin Adjuvant (HERA) trial // Lancet. 2017. Vol. 389. Р. 1195–205. doi: 10.1016/S0140-6736(16)32616-2.Cameron D., Pickart-Gebhart M.J., Gelber R.D. et al. Eleven-year follow-up of patients treated with trastuzumab after adjuvant chemotherapy for HER2-positive early breast cancer: a final analysis of the HERceptin Adjuvant (HERA) trial // Lancet. 2017. Vol. 389. Р. 1195–205. doi: 10.1016/S0140-6736(16)32616-2.Perez E.A., Romond E.H., Suman W.J. et al. Trastuzumab in combination with adjuvant chemotherapy in human epidermal growth factor receptor 2-positive breast cancer: a planned pooled analysis of overall survival from NSABP B-31 and NCCTG N9831 // J. Clin. Oncol. 2014. Vol. 32. Р. 3744–3752. doi: 10.1200/JCO.2014.55.5730.Perez E.A., Romond E.H., Suman W.J. et al. Trastuzumab in combination with adjuvant chemotherapy in human epidermal growth factor receptor 2-positive breast cancer: a planned pooled analysis of overall survival from NSABP B-31 and NCCTG N9831 // J. Clin. Oncol. 2014. Vol. 32. Р. 3744–3752. doi: 10.1200/JCO.2014.55.5730.Lux M.P., Nabieva N., Hartkopf A.D. et al. Therapeutic landscape in patients with metastatic HER2-positive breast cancer: data from the real-world breast cancer registry PRAEGNANT // Cancers (Basel). 2018. Vol. 11. Р. 10. doi: 10.3390/cancers11010010.Lux M.P., Nabieva N., Hartkopf A.D. et al. Therapeutic landscape in patients with metastatic HER2-positive breast cancer: data from the real-world breast cancer registry PRAEGNANT // Cancers (Basel). 2018. Vol. 11. Р. 10. doi: 10.3390/cancers11010010.Vernieri C., Milano M., Brambilla M. et al. Mechanisms of resistance to anti-HER2 therapy in HER2-positive breast cancer: current knowledge, new research directions, and therapeutic perspectives // Crit. Rev. Oncol. Hematol. 2019. Vol. 139. Р. 53–66. doi: 10.1016/j.critrevonc.2019.05.001.Vernieri C., Milano M., Brambilla M. et al. Mechanisms of resistance to anti-HER2 therapy in HER2-positive breast cancer: current knowledge, new research directions, and therapeutic perspectives // Crit. Rev. Oncol. Hematol. 2019. Vol. 139. Р. 53–66. doi: 10.1016/j.critrevonc.2019.05.001.Pandey K., Ahn H.-J., Kim S.K., Lee S.A., Kim S., Lim S.M. et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review // Int. J. Cancer. 2019. Vol. 145. Р. 1179–1188. doi: 10.1002/ijc.32020.Pandey K., Ahn H.-J., Kim S.K., Lee S.A., Kim S., Lim S.M. et al. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review // Int. J. Cancer. 2019. Vol. 145. Р. 1179–1188. doi: 10.1002/ijc.32020.Kitagawa M., Higashi H., Jung H.K. et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2 // EMBO J. 1996. Vol. 15. Р. 7060–7069. doi: 10.1002/j.1460-2075.1996.tb01097.x.Kitagawa M., Higashi H., Jung H.K. et al. The consensus motif for phosphorylation by cyclin D1-Cdk4 is different from that for phosphorylation by cyclin A/E-Cdk2 // EMBO J. 1996. Vol. 15. Р. 7060–7069. doi: 10.1002/j.1460-2075.1996.tb01097.x.Narasimha A.M., Kaulich M., Shapiro G.S. et al. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation // Elife. 2014. Vol. 3. Р. e02872. doi: 10.7554/eLife.02872.Narasimha A.M., Kaulich M., Shapiro G.S. et al. Cyclin D activates the Rb tumor suppressor by mono-phosphorylation // Elife. 2014. Vol. 3. Р. e02872. doi: 10.7554/eLife.02872.Ezhevsky S.A., Ho A., Becker-Hapak M. et al. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo // Mol. Cell Biol. 2001. Vol. 21. Р. 4773–4784. doi: 10.1128/MCB.21.14.4773-4784.2001.Ezhevsky S.A., Ho A., Becker-Hapak M. et al. Differential regulation of retinoblastoma tumor suppressor protein by G(1) cyclin-dependent kinase complexes in vivo // Mol. Cell Biol. 2001. Vol. 21. Р. 4773–4784. doi: 10.1128/MCB.21.14.4773-4784.2001.Goel S., Wang Q., Watt A.C. et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors // Cancer Cell. 2016. Vol. 29. Р. 255–269. doi: 10.1016/j.ccell.2016.02.006.Goel S., Wang Q., Watt A.C. et al. Overcoming therapeutic resistance in HER2-positive breast cancers with CDK4/6 inhibitors // Cancer Cell. 2016. Vol. 29. Р. 255–269. doi: 10.1016/j.ccell.2016.02.006.Tolaney S.M., Wardley A.M., Zambelli S. et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomized, open-label, phase 2 trial // Lancet Oncol. 2020. Vol. 21. Р. 763–775. doi: 10.1016/S1470-2045(20)30112-1.Tolaney S.M., Wardley A.M., Zambelli S. et al. Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): a randomized, open-label, phase 2 trial // Lancet Oncol. 2020. Vol. 21. Р. 763–775. doi: 10.1016/S1470-2045(20)30112-1.Gianni L., Bisagni G., Colleoni M. et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study // Lancet Oncol. 2018. Vol. 19. Р. 249–256. doi: 10.1016/S1470-2045(18)30001-9.Gianni L., Bisagni G., Colleoni M. et al. Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study // Lancet Oncol. 2018. Vol. 19. Р. 249–256. doi: 10.1016/S1470-2045(18)30001-9.Ciruelos E., Villagrasa P., Pascual T. et al. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial // Clin. Cancer Res. 2020. Vol. 26. Р. 5820–5829. doi: 10.1158/1078-0432.CCR-20-0844.Ciruelos E., Villagrasa P., Pascual T. et al. Palbociclib and trastuzumab in HER2-positive advanced breast cancer: results from the phase II SOLTI-1303 PATRICIA trial // Clin. Cancer Res. 2020. Vol. 26. Р. 5820–5829. doi: 10.1158/1078-0432.CCR-20-0844.Goel S., Pernas S., Tan-Wasielewski Z. et al. Ribociclib plus trastuzumab in advanced HER2-positive breast cancer: results of a phase 1b/2 trial // Clin. Breast Cancer. 2019. Vol. 19. Р. 399–404. doi: 10.1016/j.clbc.2019.05.010.Goel S., Pernas S., Tan-Wasielewski Z. et al. Ribociclib plus trastuzumab in advanced HER2-positive breast cancer: results of a phase 1b/2 trial // Clin. Breast Cancer. 2019. Vol. 19. Р. 399–404. doi: 10.1016/j.clbc.2019.05.010.Janni W., Fehm T.N., Mueller V. et al. Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer — Second interim efficacy analysis of the randomized phase III DETECT V trial // Ann. Oncol. 2024. Vol. 35, Suppl. 2. S362. doi: 10.1016/j.annonc.2024.08.298.Janni W., Fehm T.N., Mueller V. et al. Omission of chemotherapy and addition of the CDK4/6 inhibitor ribociclib in HER2-positive and hormone-receptor positive metastatic breast cancer — Second interim efficacy analysis of the randomized phase III DETECT V trial // Ann. Oncol. 2024. Vol. 35, Suppl. 2. S362. doi: 10.1016/j.annonc.2024.08.298.

The authors declare that there are no conflicts of interest present.